Mode
Text Size
Log in / Sign up
Phase 4 N=44 Randomized Triple-blind Treatment

The Impact of Arousal Threshold in Obstructive Sleep Apnea

Obstructive Sleep Apnea

Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Apnea Hypopnea Index (AHI) — 50.0; 51.8 events/hour — p=0.576

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Donepezil (Drug); placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of California, San Diego
Primary completion
May 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Apnea Hypopnea Index (AHI)
50.0; 51.8 0.576
SECONDARY
Respiratory Arousal Threshold
-18.0; -18.9 0.394

Summary

The investigators hypothesis is that obstructive sleep apnea (OSA) patients with a low arousal threshold may wake up too early during a respiratory event, before upper airway muscles can be activated to achieve stable ventilation. Thus, strategies to manipulate the respiratory arousal threshold could potentially improve the quality of sleep and sleep disordered breathing. Agents that raise arousal threshold are therefore likely to benefit some patients with OSA. The overall goal of this project is to determine the importance of the arousal threshold in OSA, determine which patients might benefit from a raised arousal threshold, and test this hypothesis by using pharmacological manipulation of the arousal threshold to achieve this goal.

Eligibility Criteria

Inclusion Criteria

  • Ages 18-70 years
  • sleep study (with apnea hypopnea index>5)
  • Diagnosis of obstructive sleep apnea

Exclusion Criteria

  • Any known unstable cardiac (apart from treated hypertension), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, or hepatic disease.
  • Susceptible to stomach ulcers.
  • Pregnant women or Nursing mothers
  • Using positive airway pressure (PAP) therapy over one week or longer
  • Body weight 5/day), alcohol (>3oz/day) or use of illicit drugs.
  • More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.
  • Deprived from sleep in the recent one week
  • Desaturations to below 70% lasting greater than 10 seconds in duration per event in the sleep study (without Oxygen).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02264353). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search